Fixed-dose combination
Ethinyl estradiol and Etonogestrel is a fixed-dose combination of an estrogen and a progestin indicated by females of reproductive age to prevent pregnancy. It is available as extended-release vaginal inserts and vaginal rings. MedsAcross supplies Ethinyl estradiol and Etonogestrel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
FOR VAGINAL USE ONLY NuvaRing ® is indicated for use by females of reproductive age to prevent pregnancy. NuvaRing is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.
Source: US FDA prescribing information
Combination hormonal contraceptives act by suppression of gonadotropins. Although the primary effect of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).
Source: US FDA prescribing information
One NuvaRing is inserted in the vagina. The ring must remain in place continuously for three weeks, followed by a one-week ring-free interval. How to Use NuvaRing To achieve maximum contraceptive effectiveness, NuvaRing must be used as directed. The ring is to remain in place continuously for three weeks. It is removed for a one-week break, during which a withdrawal bleed usually occurs. A new ring is inserted one week after the last ring was removed. The user can choose the insertion position that is most comfortable to her, for example, standing with one leg up, squatting, or lying down. The ring is to be compressed and inserted into the vagina. The exact position of NuvaRing inside the vagina is not critical for its function. The vaginal ring must be inserted on the appropriate day and left in place for three consecutive weeks.
Source: US FDA prescribing information
NuvaRing is contraindicated in females who are known to have or develop the following conditions: A high risk of arterial or venous thrombotic diseases. Examples include women who are known to: Smoke, if over age 35 Have deep vein thrombosis or pulmonary embolism, now or in the past Have cerebrovascular disease Have coronary artery disease Have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) Have inherited or acquired hypercoagulopathies Have uncontrolled hypertension Have diabetes mellitus with vascular disease Have headaches with focal neurological symptoms or migraine headaches…
Source: US FDA prescribing information
Boxed warning (cigarette smoking and serious cardiovascular events): Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including NuvaRing, should not be used by women who are over 35 years of age and smoke. Vascular risks: Stop NuvaRing use if a thrombotic event occurs. Stop NuvaRing use at least 4 weeks before and through 2 weeks after major surgery. Start no earlier than 4 weeks after delivery, in women who are not breastfeeding. Toxic Shock Syndrome (TSS): If patient exhibits signs or symptoms of TSS, consider the possibility of this diagnosis and initiate appropriate medical evaluation and treatment. Liver disease: Discontinue NuvaRing use if jaundice develops.
Source: US FDA prescribing information
The following serious adverse reactions with the use of CHCs are discussed elsewhere in the labeling. Serious cardiovascular events and stroke Vascular events Liver disease Adverse reactions commonly reported by CHC users are: Irregular uterine bleeding Nausea Breast tenderness Headache The most common adverse reactions (≥2%) in clinical trials were: vaginitis, headache (including migraine), mood changes (e.g., depression, mood swings, mood altered, depressed mood, affect lability), device-related events (e.g., expulsion/discomfort/foreign body sensation), nausea/vomiting, vaginal discharge, increased weight, vaginal discomfort, breast pain/discomfort/tenderness, dysmenorrhea, abdominal pain, acne, and decreased libido.
Source: US FDA prescribing information
Consult the labeling of all concurrently-used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations. Drugs or herbal products that induce certain enzymes, such as CYP3A4, may decrease the effectiveness of CHCs or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with CHCs.
Source: US FDA prescribing information
Prior to dispensing to the user, store refrigerated 2°C to 8°C (36°F to 46°F). After dispensing to the user, NuvaRing can be stored for up to 4 months at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F). Avoid storing NuvaRing in direct sunlight or at temperatures above 30°C (86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Ethinyl estradiol and Etonogestrel, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| NuvaRing 0.015 mg/0.12 mg per day extended-release vaginal insertVaginal Cold chain | Ethinyl estradiol and Etonogestrel | Organon | US FDA | Available on request |
| Ethinyl estradiol and Etonogestrel 0.015 mg/0.12 mg per day extended-release vaginal insertVaginal Cold chainGeneric name | Ethinyl estradiol and Etonogestrel | — | US FDA | Available on request |
| Ethinyl estradiol and Etonogestrel 0.015 mg/0.12 mg per day vaginal ringVaginal Cold chainGeneric name | Ethinyl estradiol and Etonogestrel | — | US FDA | Available on request |
| EluRyng 0.015 mg/0.12 mg per day vaginal ringVaginal Cold chain | Ethinyl estradiol and Etonogestrel | Amneal Pharmaceuticals | US FDA | Available on request |
| EnilloRing 0.015 mg/0.12 mg per day vaginal ringVaginal Cold chain | Ethinyl estradiol and Etonogestrel | Xiromed | US FDA | Available on request |
3 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 3 October 2001 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 5 presentations of Ethinyl estradiol and Etonogestrel and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 3 brand names for Ethinyl estradiol and Etonogestrel, including EluRyng, EnilloRing, NuvaRing.
Yes. The US FDA first approved Ethinyl estradiol and Etonogestrel on 3 October 2001, according to Drugs@FDA.
At least one listed presentation of Ethinyl estradiol and Etonogestrel must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.